Evidence map›Paper›PMID 34062722›Full record

ReviewPathogens (Basel, Switzerland)2021

Applications of Catechins in the Treatment of Bacterial Infections.

Meishan Wu, Angela C Brown

Open access · goldAbstract readReview
In one paragraph

Review in Pathogens (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.

0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
9.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

49 citing papers in PubMed, 91 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. A Review of the Impact of Green Tea (Current pharmaceutical design · 2026
    Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Flavonoids Identified inMolecules (Basel, Switzerland) · 2025
    Article
  13. Use ofAntibiotics (Basel, Switzerland) · 2025
    Article
  14. Review
  15. Review
  16. Green Tea: Current Knowledge and Issues.Foods (Basel, Switzerland) · 2025
    Review
  17. Review
  18. Review
  19. Specialized metabolites present inFrontiers in plant science · 2025
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Meishan WuDepartment of Chemical and Biomolecular Engineering, Lehigh University, Bethlehem, PA 18015, USA.
Angela C BrownDepartment of Chemical and Biomolecular Engineering, Lehigh University, Bethlehem, PA 18015, USA.ORCID 0000-0003-1038-8216
Lehigh University · US

Funding

National Science Foundation 1554417NIH HHS DE027769
6 · The paper itself

Abstract

Tea is the second most commonly consumed beverage worldwide. Along with its aromatic and delicate flavors that make it an enjoyable beverage, studies report numerous health advantages in tea consumption, including applications in antimicrobial therapy. The antimicrobial properties of tea are related to catechin and its derivatives, which are natural flavonoids that are abundant in tea. Increasing evidence from in vitro studies demonstrated antimicrobial effects of catechins on both gram-positive and gram-negative bacteria, and proposed direct and indirect therapeutic mechanisms. Additionally, catechins were reported to be effective anti-virulence agents. Furthermore, a number of studies presented evidence that catechins display synergistic effects with certain antibiotics, thus potentiating the activity of antibiotics in resistant bacteria. Despite their numerous beneficial properties, catechins face many challenges in their development as therapeutic agents, including poor absorption, low bioavailability, and rapid degradation. The introduction of nanobiotechnology provides target-based and stable delivery, which enhances catechin bioavailability and optimizes drug efficacy. As further research continues to focus on overcoming the unresolved challenges, catechins are likely to see additional promising applications in our continual fight against bacterial infections.

Indexed as

antibacterialantibiotic resistanceanti-virulencecatechinstoxin

Identifiers

PMID34062722
PMCPMC8147231
OpenAlexW3158725952

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.